research Janus kinase inhibitor as a therapeutic option in alopecia areata. Case report
JAK inhibitors like tofacitinib can effectively treat severe alopecia areata.
Search
for
Sort by
Research
630-660 / 1000+ results research Folliculitis decalvans responsive to tofacitinib: A case series
Tofacitinib may effectively treat folliculitis decalvans.
research Ritlecitinib in severe alopecia areata: a profile of its use
Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.
research Nilotinib-induced generalized keratosis pilaris: Report of a rare case
Nilotinib can cause generalized keratosis pilaris.
research Severe Refractory Scarring Alopecia Associated With Combinational Use of Ficlatuzumab (AV-299) and Gefitinib
Combining Ficlatuzumab and Gefitinib can cause severe hair loss.
research Ritlecitinib: First Approval
Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.
research 471 Senolytic Potential of Fisetin and ABT Compounds in Dermal Fibroblasts
research ORAL TOFACITINIB IN MODERATE AND SEVERE ALOPECIA AREATA: CASE SERIES OF 14 PATIENTS
Tofacitinib helped regrow hair in most patients with severe hair loss.
research Central nervous system demyelination associated with tofacitinib use in alopecia areata: A case report and literature review
Tofacitinib may cause nerve damage in the brain, so monitor for neurological symptoms.
research Oral and Topical Janus Kinase Inhibitors in Patients With Cutaneous T‐Cell Lymphoma: A Real‐World Single‐Center Experience
Janus kinase inhibitors may help treat cutaneous T-cell lymphoma, but more research is needed.
research 43647 Treatment of Refractory Folliculitis Decalvans with the Topical JAK Inhibitor Tofacitinib
Topical tofacitinib helped a man with severe scalp condition after other treatments failed.
research How useful is ritlecitinib in alopecia areata?
Ritlecitinib helps regrow hair in alopecia areata and is safe for long-term use.
research In‐silico Screening of ATP‐competitive Inhibitory Activities of Phytochemicals against Janus Kinase 3 and Its In‐vitro Evaluation
Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.
research 075 Clinical investigation of JAK inhibitor Tofacitinib in scarring alopecias
Tofacitinib may slow hair loss in scarring alopecias but is unlikely to regrow significant hair.
research Efficacy of tofacitinib in treatment of alopecia universalis in two patients
Tofacitinib was effective in treating hair loss in two patients with alopecia universalis.
research Drug Survival and Long-term Outcome of Tofacitinib in Patients with Alopecia Areata: A Retrospective Study
Tofacitinib is effective and safe for treating alopecia areata with a good drug survival rate.
research Alopecia areata
Alopecia areata is an autoimmune condition causing hair loss, influenced by genetics, stress, and diet, and may be prevented by a high soy oil diet.
research JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis
JAK inhibitors are effective in treating various immune-related diseases, not just rheumatoid arthritis.
research Alopecia areata: a review of disease pathogenesis
Alopecia areata is likely an autoimmune disease with unclear triggers, involving various immune cells and molecules, and currently has no cure.
research Alopecia areata
Some treatments can help with a hair loss condition called alopecia areata, but none ensure lasting results; choices depend on the person, with JAK inhibitors showing promise for severe cases.
research Pharmacologic inhibition of JAK-STAT signaling promotes hair growth
Blocking JAK-STAT signaling can lead to hair growth.
research Targeting the Janus Kinase Family in Autoimmune Skin Diseases
Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.
research Hair Follicle Immune Privilege Revisited: The Key to Alopecia Areata Management
Restoring hair bulb immune privilege is crucial for managing alopecia areata.
research Cutaneous manifestations and considerations in COVID ‐19 pandemic: A systematic review
COVID-19 can cause skin issues like rashes and "COVID toes," and people with skin conditions should adjust their treatments if they get the virus.
research Treatment of alopecia areata: An Australian expert consensus statement
Alopecia areata treatment varies, with no optimal method established yet.
research Human αβ and γδ T Cells in Skin Immunity and Disease
Certain types of T cells are essential for healthy skin and play a role in skin diseases, but more research is needed to improve treatments.
research Alopecia areata: Animal models illuminate autoimmune pathogenesis and novel immunotherapeutic strategies
Animal models have helped understand hair loss from alopecia areata and find new treatments.
research Understanding autoimmunity of vitiligo and alopecia areata
Both vitiligo and alopecia areata involve an immune response triggered by stress and specific genes, with treatments targeting this pathway showing potential.
research The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases
Janus kinase inhibitors are promising drugs for treating autoimmune and inflammatory diseases.
research A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata
Apremilast was not effective in treating moderate-to-severe alopecia areata.